Latest News-Telix Pharmaceuticals Corporate Limited Mediaroom_Page

Telix to Supply Bayer with Illuccix® for Global Phase III Prostate Cancer Study

MELBOURNE, Australia, May 8, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, t...

2023-05-08 05:00 5267

Telix to Supply Bayer with Illuccix® for Global Phase III Prostate Cancer Study, including Japanese Sites

MELBOURNE, Australia and KYOTO, Japan, May 8, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (A...

2023-05-08 05:00 2212

First Patients in Canada Imaged with Illuccix®: Now Commercially Available Nationwide

MELBOURNE, Australia, May 2, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, t...

2023-05-02 05:00 2101

ZIRCON Phase III Kidney Cancer Imaging Study Presented at AUA: New Data Confirms Efficacy in Masses 2cm or Smaller

MELBOURNE, Australia, May 1, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, t...

2023-05-01 08:58 2478

Telix Accelerates Artificial Intelligence (AI) Development Program with Acquisition of Dedicaid

MELBOURNE, Australia, April 27, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix...

2023-04-27 06:50 2359

Telix Reports Q1 2023 Financial Results: Delivers First $100M Revenue Quarter

MELBOURNE, Australia, April 17, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix...

2023-04-17 18:15 2026

Olaratumab Antibody Licensed from Lilly Demonstrates Proof of Concept as a Theranostic Radiopharmaceutical

MELBOURNE, Australia, April 17, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix...

2023-04-17 06:38 1730

Chinese NMPA Approves Study of Telix Brain Cancer Therapy Candidate

MELBOURNE, Australia, April 11, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix...

2023-04-11 05:00 1948

FDA Approves Expanded Indication for Telix's Illuccix® to Include Patient Selection for PSMA-Directed Radioligand Therapy

INDIANAPOLIS, March 16, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Co...

2023-03-16 20:28 1676

FDA Approves Expanded Indication for Telix's Illuccix® to Include Patient Selection for PSMA-Directed Radioligand Therapy

MELBOURNE, Australia, March 16, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix...

2023-03-16 08:28 2144

Telix's ZIRCON Phase III Kidney Cancer Imaging Study Presented in "Game Changing" Session at EAU

MELBOURNE, Australia, March 14, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix...

2023-03-14 05:11 1632

Telix to Showcase Additional ZIRCON Phase III Data in Kidney Cancer Imaging and Theranostic Pipeline Developments at EAU

MELBOURNE, Australia, March 9, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix,...

2023-03-09 04:51 2091

Telix 2022 Full Year Results: Revenue up 20x in first year of commercial sales, underpins transition to cash flow positive

MELBOURNE, Australia, Feb. 27, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix,...

2023-02-27 14:37 1719

Latest News

Telix to Supply Bayer with Illuccix® for Global Phase III Prostate Cancer Study

Telix to Supply Bayer with Illuccix® for Global Phase III Prostate Cancer Study, including Japanese Sites

First Patients in Canada Imaged with Illuccix®: Now Commercially Available Nationwide

ZIRCON Phase III Kidney Cancer Imaging Study Presented at AUA: New Data Confirms Efficacy in Masses 2cm or Smaller

Telix Accelerates Artificial Intelligence (AI) Development Program with Acquisition of Dedicaid

Telix Reports Q1 2023 Financial Results: Delivers First $100M Revenue Quarter

Olaratumab Antibody Licensed from Lilly Demonstrates Proof of Concept as a Theranostic Radiopharmaceutical

Chinese NMPA Approves Study of Telix Brain Cancer Therapy Candidate

FDA Approves Expanded Indication for Telix's Illuccix® to Include Patient Selection for PSMA-Directed Radioligand Therapy

FDA Approves Expanded Indication for Telix's Illuccix® to Include Patient Selection for PSMA-Directed Radioligand Therapy

Telix's ZIRCON Phase III Kidney Cancer Imaging Study Presented in "Game Changing" Session at EAU

Telix to Showcase Additional ZIRCON Phase III Data in Kidney Cancer Imaging and Theranostic Pipeline Developments at EAU

Telix 2022 Full Year Results: Revenue up 20x in first year of commercial sales, underpins transition to cash flow positive

Detailed Results from Telix's ZIRCON Phase III Kidney Cancer Imaging Study Presented at ASCO GU

Telix Collaboration on Next Generation Urologic-Oncology Theranostic Published in Journal of Nuclear Medicine

Telix Reports Fourth Quarter 2022 Financial Results

Presentation to J.P. Morgan Healthcare Conference and Q4 2022 Illuccix Revenue Update

ZIRCON Phase III Renal Cancer Study to be Presented at ASCO GU along with Theranostic Pipeline Advances

Telix Announces Executive Leadership Appointments

Illuccix® Available on High Activity Gallium Generator Technology to Meet High Demand